Sou Hu Cai Jing·2026-01-22 11:25Core Viewpoint - Spring Medical (688236) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The net profit excluding non-recurring items was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, soaring by 531.12% year-on-year [2]. - The quarterly net profit excluding non-recurring items was 74.52 million yuan, up 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 22, 2026, Spring Medical's stock closed at 26.6 yuan, down 0.64%, with a turnover rate of 0.72% and a trading volume of 20,700 hands, amounting to a transaction value of 55.49 million yuan [1]. - On January 22, the net outflow of main funds was 4.5364 million yuan, accounting for 8.18% of the total transaction value, while retail investors saw a net inflow of 1.1627 million yuan, representing 2.1% of the total [1]. Analyst Ratings - In the last 90 days, 8 institutions have rated Spring Medical with a "buy" recommendation, and the average target price set by these institutions is 31.7 yuan [3].